Breaking News, Financial News

Financial Report: Amgen 1Q

Product sales were up 13% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen   1Q Revenues: $5.0 billion (+11%) 1Q Earnings: $1.6 billion (+51%) Comments: Product sales were up 13% driven by Enbrel (+13% to $1.1 billion), Prolia (+39% to $170 million), EPOGEN (+16% to $534 million), Sensipar (+24% to $241 million) and XGEVA (+22% to $245 million). Neulasta/NEUPOGEN sales were flat at $1.1 billion. Unfavorable changes in foreign exchange rates impacted revenue by 2 percentage points. R&D expenses were down 14% to $856 million....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters